Financial Shenanigans

Financial Shenanigans

Daqo's reported numbers look like a faithful, if unflattering, picture of a deep-cyclical Chinese commodity producer at the bottom of a polysilicon glut. There is no restatement, no auditor qualification, no admitted misconduct, and the balance sheet still carries roughly $2.0B of cash and term deposits with zero bank debt. The forensic concerns concentrate in four places: (1) family-and-parent-group governance that limits independent challenge – including a Compensation Committee chaired by the Daqo Group's Vice President for Finance, whom the company itself acknowledges does not satisfy NYSE independence; (2) cash-flow presentation around bank acceptance notes, where FY2025 notes payable of $98.8M exceeded total CFO; (3) judgment-driven impairment timing that produced a clean 2025 P&L despite continued ASP weakness (2024 big bath / 2025 reset asymmetry); and (4) a sharp jump in receivables (+146%) against a 35% revenue decline, paired with an explicit "long-aged receivables" credit-loss allowance. On January 6, 2026, SAMR halted the antitrust review of the proposed privatization SPV, adding regulatory overhang.

The single data point that would most change this assessment is whether FY2026 operating cash flow remains positive after notes payable and notes receivable normalize, without new allowance, write-off, or impairment pressure.

The Forensic Verdict

Shenanigans Scorecard

Breeding Ground

The structural conditions favor aggressive reporting more than the reported numbers themselves do. Three lines of concern overlap: founder/family control, parent-group entanglement, and a controlled-subsidiary listing in Shanghai that creates a permanent tax-and-dividend channel between the Cayman parent and Chinese-listed Xinjiang Daqo (Daqo Cayman owns roughly 71.66% of Xinjiang Daqo).

The Compensation Committee structure is the single hardest item to defend. The chair is a senior officer of the parent Daqo Group, the company itself does not claim he is independent, and a committee that meets only via written consent during a year with $55.8M of SBC and a 30-year-old family member promotion to Deputy CEO is exactly the kind of structure where outside investors would expect more friction. NYSE allows a controlled-company exemption, but the company does not currently invoke it.

Earnings Quality

Reported earnings track the polysilicon cycle with credible fidelity, but the quality of the bottom line rises and falls on impairment judgments, inventory write-down decisions, a credit-loss allowance that arrived only after receivables had aged, and SBC that held high as revenue collapsed.

Revenue fell 35.3% in FY2025, but notes receivable increased 145.7%. That is not automatically a revenue-recognition failure because notes receivable are bank acceptance drafts and the company says substantially all sales require advance payments before shipment. It still raises collection-quality risk because Deloitte separately identified revenue cut-off for domestic polysilicon sales as a critical audit matter, and FY2025 DSO rose to 52.3 days from 30.4 days. Management discloses "uncertainties in recoverability of long-aged receivables" and books a $19.3M expected credit loss for the second consecutive year (zero in 2023, $18.1M in 2024). The combination of an end-of-cycle volume push plus an aging receivable book plus a fresh credit-loss reserve is consistent with extending credit to keep customers buying.

Inventory days rose to 72.5 in FY2025 as utilization stayed low (~41% of 305,000 MT capacity), while DPO rose to 37.0. The pattern is consistent with a cyclical producer managing through oversupply, but it makes the balance sheet less clean than the income statement alone suggests. DSO and inventory days are not in management's headline KPI panel – an investor who relies only on management's deck will not see the FY2025 receivable build until they read the balance sheet.

Big-Bath Asymmetry

The 2024 charges concentrated three judgment items in the same loss year: $175.6M of long-lived asset impairment on older polysilicon lines, $108M of Q2 non-cash inventory write-down (cost above market), and the first-ever $18.1M credit-loss allowance. In 2025 the long-lived asset test was reset to zero, with management citing a polysilicon ASP "rebound" – but the full-year 2025 ASP of $5.25/kg was 7.3% below the 2024 average of $5.66/kg. The impairment reset is defensible if Q4 ASP and 2026 expectations support the carrying value, but it is not symmetric with what the income statement shows. FY2025 gross margin remained negative 20.7%.

SBC Trend

SBC is now the single largest cushion under operating cash flow. In FY2025, the $55.8M SBC add-back exceeds the $49.7M reported CFO, meaning underlying operating cash before SBC was negative. Cumulative RSU grants total 94.3M versus 67.7M shares outstanding. The Compensation Committee that oversees these awards is chaired by a non-independent Daqo Group officer, and met only once in 2025 (by written consent).

Cash Flow Quality

Cash flow quality is the weakest part of the forensic file. FY2025 CFO turned positive, but free cash flow remained negative and the bridge depended on non-cash charges plus bank-note working capital.

Two periods break the normal "CFO approximates NI" pattern:

1. FY2023: consolidated NI $653M, CFO $1,616M, ratio 2.48x. The gap is overwhelmingly the $1.0B drawdown in receivables from $1,131.6M to $116.4M as the polysilicon market normalized. This is recoverable cash, not a manipulation, but it is a non-recurring tailwind that ended in 2024.
2. FY2024-FY2025: CFO turned negative in 2024 (-$435M) and printed only $50M in 2025. Once the working-capital release ended, CFO collapsed.

Over the last three fiscal years, CFO was positive $1.23B while FCF was negative $412.3M and consolidated net income was close to break-even. That mix is not a fraud signal by itself in a capex-heavy commodity business, but it says valuation should not capitalize CFO as though it were recurring free cash generation.

Notes-Payable Red Flag

The core mechanism in FY2025: notes payable contributed $98.8M of operating cash flow – more than total FY2025 CFO of $49.7M – while notes receivable used $76.3M and inventory used $34.3M. The filing says notes payable are bank-issued supplier notes that extend payment terms and do not represent cash borrowings because they are repaid using restricted cash and deposits at the same banks. That disclosure is useful, but it also means CFO is sensitive to the bank-note cycle. The notes payable balance rose from $6.8M to $103.0M in a single year. If bank notes are not renewed in FY2026, CFO would face a roughly $100M headwind.

Metric Hygiene

Management's headline disclosures are fairly disciplined for a Chinese ADR – they restate ASP, sales volume, production volume, capacity, and per-kilo production cost ($6.61/kg in 2025) every quarter, on the same definitions, with the same divisors. The most-aggressive metric is "Adjusted EBITDA," which adds back depreciation, amortization, interest, taxes, SBC, and non-cash impairments. The reconciliation is published in each earnings release.

The non-GAAP issue is not definition drift; it is economic weight. Adjusted net loss excludes only share-based compensation in the reviewed reconciliation, which is transparent, but the add-back is large relative to current revenue and appears every year. EBITDA is also heavily influenced by depreciation in a newly expanded, underutilized asset base. The notable miss is that DSO and inventory days are not in management's headline KPI panel even though receivables and inventory carry the most underwriting risk in a glut.

What to Underwrite Next

The grade hinges on disclosures that the next 20-F or quarterly release will resolve. The following watchlist merges all material items from the forensic analysis.